BRAFV600E mutation does not mean distant metastasis in thyroid papillary carcinomas.
about
Risk Stratification in Differentiated Thyroid Cancer: An Ongoing ProcessTime to re-consider the meaning of BRAF V600E mutation in papillary thyroid carcinomaIntegrated data analysis reveals potential drivers and pathways disrupted by DNA methylation in papillary thyroid carcinomas.The prognostic implication and potential role of BRAF mutation in the decision to perform elective neck dissection for thyroid cancerUpdate on anaplastic thyroid carcinoma: morphological, molecular, and genetic features of the most aggressive thyroid cancer.Association of BRAFV600E mutation with clinicopathological features of papillary thyroid carcinoma: a study on a Chinese populationImmunohistochemistry is highly sensitive and specific for detecting the BRAF V600E mutation in papillary thyroid carcinomaAssociation of BRAF V600E Mutation and MicroRNA Expression with Central Lymph Node Metastases in Papillary Thyroid Cancer: A Prospective Study from Four Endocrine Surgery CentersMicroRNA-146b: A Novel Biomarker and Therapeutic Target for Human Papillary Thyroid Cancer.The role of molecular diagnostic testing in the management of thyroid nodules.Prognostic implication of BRAF and TERT promoter mutation combination in papillary thyroid carcinoma-A meta-analysis.A combination of immunohistochemistry and molecular approaches improves highly sensitive detection of BRAF mutations in papillary thyroid cancer.BRAF V600E mutation and papillary thyroid cancer--in reply.Molecular pathology of thyroid tumours of follicular cells: a review of genetic alterations and their clinicopathological relevance.Role of molecular markers to predict distant metastasis in papillary thyroid carcinoma: Promising value of TERT promoter mutations and insignificant role of BRAF mutations-a meta-analysis.Genome-wide profiling identifies the THYT1 signature as a distinctive feature of widely metastatic Papillary Thyroid Carcinomas.Clinicopathological Risk Factors for Distant Metastasis in Differentiated Thyroid Carcinoma: A Meta-analysis.BRAF(V600E) mutation analysis in papillary thyroid carcinoma: is it useful for all patients?
P2860
Q26765083-6D2B9730-0FDA-47DC-967D-D897CCA7324AQ26853261-B74AE129-0205-48B0-835F-6A942DFCDAC1Q33629836-E845E1BE-83D2-45C1-872E-437613208F7EQ33973118-B90CFE07-D351-40C4-B25D-132E1DB1A296Q34152070-ACAD575B-8B24-420E-8E89-67AEB42D33DEQ34501707-EF02D16D-AB65-4E5F-833D-21102A079B57Q36464807-6A7CE1EC-1CA6-4377-9E70-1FA3DA3C0DABQ36786213-E450D1B3-1BF3-4EA9-8E30-57F33A7E8C9FQ39179286-D598A73A-0DDD-4598-B2B7-F05931D45FE3Q39250953-CFCDED13-7976-457F-8B92-B8B2D230D50AQ39407370-9902C113-A9BB-4067-BE53-2DFFB90515DAQ40619094-DDCC32FA-5C3F-4DAC-B548-37BB04392083Q42940129-A0D3DCBD-A2DF-4772-95E7-E5EA63396DEFQ47295202-D67BC42F-8A22-442F-9BC2-C4B65D1FCC06Q47646209-621BAF5A-F4FB-4B6B-858C-BABDB3BF9E34Q49197249-904A99BE-11D2-4D2E-B0C9-D7CE504B1644Q50075399-8D291A0E-189B-4B93-AE39-9F695A67A20AQ54407999-9B74E5D1-E146-400F-99F2-7908E43DB583
P2860
BRAFV600E mutation does not mean distant metastasis in thyroid papillary carcinomas.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh-hant
name
BRAFV600E mutation does not mean distant metastasis in thyroid papillary carcinomas.
@en
BRAFV600E mutation does not mean distant metastasis in thyroid papillary carcinomas.
@nl
type
label
BRAFV600E mutation does not mean distant metastasis in thyroid papillary carcinomas.
@en
BRAFV600E mutation does not mean distant metastasis in thyroid papillary carcinomas.
@nl
prefLabel
BRAFV600E mutation does not mean distant metastasis in thyroid papillary carcinomas.
@en
BRAFV600E mutation does not mean distant metastasis in thyroid papillary carcinomas.
@nl
P2093
P356
P1476
BRAFV600E mutation does not mean distant metastasis in thyroid papillary carcinomas.
@en
P2093
Davide Nicoli
Moira Ragazzi
Simonetta Piana
P304
P356
10.1210/JC.2012-1526
P407
P577
2012-06-27T00:00:00Z